Diana Saraceni, partner di Panakes Partners, è stata intervistata da Wired Italia sull’importanza degli investimenti in deep tech e sull’attività della Commissione europea, che ha creato il Trusted investors network, un gruppo di 71 fondi di venture capital con cui Bruxelles intende lavorare in tandem per far crescere le startup più promettenti, selezionate dal Consiglio europeo dell'innovazione (Eic). 👉🏻 https://lnkd.in/dve_2EAU Thanks Luca Zorloni
Chi siamo
Panakès Partners is a Venture Capital firm, based in Milan, which invests in the most ambitious companies and teams, developing revolutionary technologies and products, in the field of life sciences, aiming to improve the lives of people around the world, in two funds. Panakès, founded in 2015 by Fabrizio Landi, Alessio Beverina and Diana Saraceni, has 250 million under management. Panakes brings strong entrepreneurial and financial expertise to portfolio companies well beyond just capital, relying on a wide network of clinicians and industry experts. We have established relationships with selected industrial partners to assist our founders in accelerating their development. We invest in people, believing that a strong and dedicated team is one of the most important factors in the success of our investments. We aim to work together with entrepreneurs to develop successful businesses as an active and well-connected investor. We invest for people, supporting the growth of companies and people that will reshape the medical world, answering real medical needs, saving lives and providing a better quality of life for patients and care-givers. An overall positive impact that will produce intrinsic value for both investors and society. Panakes derives from Panacea (Greek Πανάκεια, Panakeia), who was the goddess of Universal remedy, said to have a potion with which she healed the sick.
- Sito Web
-
http://www.panakes.it
Link esterno per Panakes Partners
- Settore
- Mandanti di venture capital e private equity
- Dimensioni dell’azienda
- 11-50 dipendenti
- Sede principale
- Milano
- Tipo
- Società privata non quotata
- Data di fondazione
- 2015
- Settori di competenza
- Venture CAPITAL, Diagnostics, Medtech, Biotech e Digital therapeutics
Località
-
Principale
Ottieni indicazioni
via Boscovich 31
Milano, 20124, IT
Dipendenti presso Panakes Partners
Aggiornamenti
-
Panakes Partners' portfolio company DISCO Pharmaceuticals GmbH won the European Lifestars Awards - Celebrating Life Science Leadersfor the Seed Raise of the Year award. Great work from DISCO team !
Wow! What an amazing evening at the European Lifestars Awards - Celebrating Life Science Leaders 🌠, where DISCO Pharmaceuticals GmbH was presented with the Seed🌱 Raise of the Year award 👏. Big shoutout 📣 to the 🥳 DISCO team for all your hard work and dedication and to our investors for supporting our mission to transform #cancer care by expanding the molecular target🎯space using our disruptive #surfaceome mapping technology. Thank you to LSX - partnering for Life Science eXecutives for the recognition and congratulations to all the winners and finalists! #LifestarsAwards #drugsdiscovery #biotech
-
-
Panakes Partners' portfolio company Enterprise Therapeutics just announced the publication in the European Journal of Medicinal Chemistry of its paper describing the discovery of ETD001, a novel inhaled blocker of the epithelial sodium channel (ENaC) for the treatment of cystic fibrosis. Read the paper here: https://lnkd.in/eGE933kJ congrats to the ETx team !
Our paper describing the discovery of ETD001, a novel inhaled blocker of the epithelial sodium channel (ENaC) for the treatment of cystic fibrosis, has been published in the European Journal of Medicinal Chemistry. Read the paper here: https://lnkd.in/eGE933kJ The paper describes the medicinal chemistry optimisation of a new series of ENaC blockers, which resulted in the invention of ETD001, our lead candidate. Prof Martin Gosling, CSO: “We firmly believe that the unique properties of ETD001, giving rise to class leading lung retention, will deliver an effective therapy to people with CF currently unable to benefit from CFTR modulators. We look forward to sharing the results of our Phase 2 study in 2025.” Phase 2 clinical trials for ETD001 commenced in July to understand whether treatment with ETD001 will improve lung function in people with cystic fibrosis.
-
-
Panakes Partners' portfolio company Nouscom has announced the completion of patient enrollment of 69 patients in a randomized Phase 2 study trial, to evaluate its lead asset, NOUS-209 in combination with pembrolizumab, in unresectable and metastatic colorectal cancer (mCRC) patients. Congrats Marina Udier-Blagovic and the overall Nouscom team ! Waiting for the efficacy readout for the primary endpoint anticipated in mid-2025! https://lnkd.in/eQMeFj99
-
Panakes Partners' portfolio company Echolight has announced that it has signed an agreement enabling Siemens Healthineers to be a reseller of Echolight bone densitometers, its radiation-free technology that allows physicians to perform repeated scans for monitoring bone health over time for osteoporosis and bone fragility. congrats to SERGIO CASCIARO and the Echolight team. https://lnkd.in/erUTrpNS
ECHOLIGHT ANNOUNCES MULTI-YEAR AGREEMENT WITH SIEMENS HEALTHINEERS
prnewswire.com
-
Alessio Beverina, partner at Panakes Partners , will be speaking on a panel alongside Lotus Qi , Robert Hornby and Joe Heanue today on a panel at the Investival Showcase in London discussing the current funding market for #MedTech companies. https://lnkd.in/eDV9QiDU
-
-
Diana Saraceni, partner at Panakes Partners, was at #MedtechMalta2024 organized by MedTech World talking about key trends and investment priorities
🎉 Big things happening at #MedTechMalta2024! Today’s spotlight: Reverse Pitch: Venture Capital! Instead of startups pitching, top VCs are taking the stage to share what they’re looking for in medtech investments. * Soyoung Park, General Partner, 1004 Venture Partners * Joshua Phillips, Co-Founder and Managing Partner, CHV * Gautam Kainth, Partner, TCP Health Ventures * Hirak Parikh, Principal, Venture Investments, JJDC, Johnson & Johnson * Diana Saraceni, General Manager, Panakes Partners * Sascha Berger, Investment Director, NEOM * David Kereiakes, Managing Partner, Windham Capital Partners * Jotthe Kannappan, Senior Associate, Intuitive Ventures 🚀 💡Moderated by Malek Nasr, this is a rare inside look into the minds of those fueling the future of health tech. They're talking about key trends, investment priorities, and what founders need to know before pitching. 🧠 Supported by: Lifeblood, Malta Enterprise, VisitMalta Incentives & Meetings, Malta Digital Innovation Authority, Ministry for Health and Active Ageing, Government of Malta. #MedTechMalta #Innovation #VentureCapital #HealthTech
-
Panakes Partners’ portfolio company MMI - Medical Microinstruments, Inc. has announced that their surgical robotic platform #Symani has been named a TIME Best Innovation in robotics in 2024 We are proud investors and happy to have supported the visionary MMI team that is dedicated to transforming patient care with robotic innovation!
Big recognition for the Symani Surgical System! We’re beyond proud to see our enabling technology named a TIME Best Invention of 2024. The system is helping surgeons push the boundaries of microsurgery and rethink the definitions of ‘treatable’ and ‘untreatable’ when it comes to complex medical conditions. Learn more about our first-of-its-kind robotic platform and see the full list of TIME’s Best Inventions: https://lnkd.in/ez_kwwXm #Innovation #RoboticSurgery #Symani #Microsurgery #Supermicrosurgery #TIMEBestInventions
-
-
Panakes Partners’ portfolio company Vivasure Medical Ltd. Just Announces Positive Results of its IDE Pivotal Study Indicating Safety and Efficacy of PerQseal® Large Hole Closure Device Data demonstrate Vivasure’s PerQseal® Closure Device achieved closure with very low rates of major vascular complications and rapid times to hemostasis. A very high exciting news for patients and healthcare professionals ! Congrats to Andrew Glass and the Vivasure team ! https://lnkd.in/dtVdEWKx
Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal® Large Hole Closure Device
businesswire.com
-
ENEA Tech e Biomedical e Panakes Partners hanno stretto un accordo di collaborazione sinergica con l’obiettivo di imprimere una spinta propulsiva al sistema imprenditoriale e al mondo dell’innovazione nel nostro Paese. L'intesa mira a supportare opportunità di networking all’interno dell’ecosistema del venture capital, con focus nell'ambito delle Scienze della Vita, al fine di favorire collaborazioni tra soggetti nel settore in Italia, individuando potenziali cooperazioni nell’attività di investimento